Mankind Pharma (Large Cap) Share Target 2025, 2026 To 2035
|
Mankind Pharma Limited |
|||
|
Price: ₹2,563.55 (-5.22%) | ||
| 52 Week Low: ₹1,901.05 52 Week High: ₹3,054.80 |
|||
| Market Capital: 1,01,695.44 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Mankind Pharma Share Price Target For 2025
- 1.1.1: Mankind Pharma Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Mankind Pharma Share Price Target For 2026
- 1.2.1: Mankind Pharma Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Mankind Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Mankind Pharma Brief Company Overview
- 4: Mankind Pharma Financial Performance
- 4.0.1: Is Mankind Pharma A Good Buy For Long Term?
Mankind Pharma, a Large Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 28.2% returns in 1-year showing 13.6% quarterly revenue growth with 19.2% profit margin.
To predict the Mankind Pharma's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Mankind Pharma Share Price Target For 2025
The line chart displays the monthly closing prices of Mankind Pharma with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Mankind Pharma shares in 2025, see the table below.
Mankind Pharma Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2810.05 (+9.61%) | Price Action: 09 Jan 2025 Low |
| 2025 Target 2 | 2780.0 (+8.44%) | Price Action: Sep 2024 High |
| 2025 Target 1 | 2741.25 (+6.93%) | Price Action: 25 Sep 2024 High |
| Current Price | 2563.55 | Mankind Pharma's share price as of 21 Jan 2025 |
| Stop Loss 1 | 2484.8 (-3.08%) | Price Action: 18 Sep 2024 High |
| Stop Loss 2 | 2453.6 (-4.29%) | Price Action: 11 Sep 2024 High |
| Stop Loss 3 | 2421.0 (-5.57%) | Price Action: 12 Sep 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Mankind Pharma is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹2698.8 serves as the nearest technical reference point.
Historical Returns: 3-month: -3.89% | 6-month: +26.4% | 1-year: +28.18%
Mankind Pharma Share Price Target For 2026
The line chart displays the monthly closing prices of Mankind Pharma with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Mankind Pharma shares in 2026, see the table below.
Mankind Pharma Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 3849.23 (+50.15%) | Price Action: Chart |
| 2026 Target 2 | 3777.46 (+47.35%) | Price Action: Chart |
| 2026 Target 1 | 3740.06 (+45.89%) | Fibonacci Extension Level 64.90% |
| Current Price | 2563.55 | Mankind Pharma's share price as of 21 Jan 2025 |
| Stop Loss 1 | 2288.25 (-10.74%) | Price Action: 19 Apr 2024 Low |
| Stop Loss 2 | 2261.6 (-11.78%) | Price Action: 08 May 2024 High |
| Stop Loss 3 | 2238.2 (-12.7%) | Price Action: 18 Jun 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Mankind Pharma is currently trading at 57.4% of its 52-week range (₹1901.05 - ₹3054.8).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +28.18% | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Mankind Pharma Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,563.55 | ||
| 2025 | ₹4,249.27 | +65.75% | ₹4,313.01 |
| 2026 | ₹5,764.74 | +35.66% | ₹5,851.21 |
| 2027 | ₹8,131.61 | +41.05% | ₹8,253.58 |
| 2028 | ₹10,054.51 | +23.64% | ₹10,205.33 |
| 2029 | ₹14,913.52 | +48.32% | ₹15,137.22 |
| 2030 | ₹20,118.27 | +34.89% | ₹20,420.04 |
| 2031 | ₹25,633.13 | +27.41% | ₹26,017.63 |
| 2032 | ₹35,613.68 | +38.93% | ₹36,147.89 |
| 2033 | ₹45,536.76 | +27.86% | ₹46,219.81 |
| 2034 | ₹58,999.03 | +29.56% | ₹59,884.02 |
| 2035 | ₹71,960.41 | +21.96% | ₹73,039.82 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Mankind Pharma Brief Company Overview
Company Overview: Mankind Pharma Limited Mankind Pharma Limited, founded in 1986, is a leading pharmaceutical company in India with a global presence. They specialize in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations and consumer...
healthcare products. Mankind Pharma's product portfolio encompasses acute and chronic therapeutics, including anti-infectives, cardiovascular medications, gastrointestinal treatments, anti-diabetics, dermatological solutions, pain/analgesics, neuro/CNS drugs, vitamins/minerals/nutrients, and respiratory medications. In addition to pharmaceuticals, they offer a wide range of consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company's commitment to innovation and quality has earned it a strong reputation in the industry. Mankind Pharma's products are marketed under well-established brand names, including Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. With a focus on customer satisfaction, Mankind Pharma is committed to providing affordable and effective healthcare solutions to meet the needs of its customers.Mankind Pharma Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,01,695.44 Crore | Market valuation of Mankind Pharma's shares. |
| Revenue (TTM) | 11,017.98 Crore | Total revenue generated by Mankind Pharma over the past twelve months. |
| Net Income (TTM) | +2,114.95 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +24.19% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +19.19% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+13.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+30.4% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
4.46 | Company's total debt divided by total shareholder equity. |
| Total Debt | 482.04 Crore | Sum of Mankind Pharma's current & long-term financial obligations. |
| Total Cash | 4,726.74 Crore | Total amount of liquid funds available to Mankind Pharma. |
Is Mankind Pharma A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
